Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-13

Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

Phase 3 trial update for baricitinib in rheumatoid arthritis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-03-13